In general, the therapeutic strategies in SMA can be categorized either as SMN-dependent therapies or as SMN-independent therapies, which can be subsequently divided into eight different therapeutic approaches (Figure 3). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.